Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

300 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.
Loibl S, Majewski I, Guarneri V, Nekljudova V, Holmes E, Bria E, Denkert C, Schem C, Sotiriou C, Loi S, Untch M, Conte P, Bernards R, Piccart M, von Minckwitz G, Baselga J. Loibl S, et al. Among authors: guarneri v. Ann Oncol. 2016 Aug;27(8):1519-25. doi: 10.1093/annonc/mdw197. Epub 2016 May 13. Ann Oncol. 2016. PMID: 27177864 Free PMC article.
High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC).
Bengala C, Pazzagli I, Innocenti F, Donati S, Favre C, Menconi MC, Greco F, Danesi R, Orlandini C, Guarneri V, Del Tacca M, Conte PF. Bengala C, et al. Among authors: guarneri v. Ann Oncol. 2001 Jan;12(1):69-74. doi: 10.1023/a:1008302402687. Ann Oncol. 2001. PMID: 11249051 Free article. Clinical Trial.
New combinations with epirubicin in advanced breast cancer.
Conte P, Gennari A, Landucci E, Guarneri V, Donati S, Salvadori B, Bengala C, Orlandini C. Conte P, et al. Among authors: guarneri v. Oncology (Williston Park). 2001 May;15(5 Suppl 7):24-7. Oncology (Williston Park). 2001. PMID: 11396361 Free article. Review.
Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer.
Gennari A, Guarneri V, Landucci E, Orlandini C, Rondini M, Salvadori B, Ricci S, Conte PF. Gennari A, et al. Among authors: guarneri v. Clin Breast Cancer. 2002 Dec;3(5):346-52. doi: 10.3816/CBC.2002.n.038. Clin Breast Cancer. 2002. PMID: 12533265 Clinical Trial.
High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study.
Bengala C, Danesi R, Guarneri V, Pazzagli I, Donati S, Favre C, Fogli S, Biadi O, Innocenti F, Del Tacca M, Mariani M, Conte PF. Bengala C, et al. Among authors: guarneri v. Bone Marrow Transplant. 2003 Feb;31(4):275-80. doi: 10.1038/sj.bmt.1703827. Bone Marrow Transplant. 2003. PMID: 12621462
Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma: results for the Gruppo Oncologico Nord Ovest randomized trial.
Conte PF, Guarneri V, Bruzzi P, Prochilo T, Salvadori B, Bolognesi A, Aldrighetti D, Venturini M, Rosso R, Mammoliti S, Carnino F, Giannessi P, Costantini M, Moyano A, Baldini E; Gruppo Oncologico Nord Ovest. Conte PF, et al. Among authors: guarneri v. Cancer. 2004 Aug 15;101(4):704-12. doi: 10.1002/cncr.20400. Cancer. 2004. PMID: 15305399 Free article. Clinical Trial.
300 results